Understanding how minoxidil works explains the timeline (why month 3 is tough), who doesn't respond (sulfotransferase enzyme), why oral outperforms topical for some men, and why beard results can be permanent while scalp results aren't. Not just biology for its own sake — it answers the real questions.
The Big Picture
Minoxidil's primary mechanism is KATP channel opening — it opens ATP-sensitive potassium channels in smooth muscle cells around blood vessels, causing those vessels to relax and dilate. Near a hair follicle, this dilation means more blood flow, more oxygen, more nutrients delivered to the dermal papilla (the follicle's command center). The result is a stimulated, enlarged follicle capable of producing thicker, longer hair.
But the story doesn't stop at vasodilation. There are at least four distinct mechanisms at work — and the interaction between them produces the full range of effects you see over a 12-to-24-month treatment course.
Step-by-Step: What Happens When You Apply Minoxidil
Conversion to Active Form — The Sulfotransferase Step
When minoxidil contacts skin, it's converted into its active form — minoxidil sulfate — by an enzyme called sulfotransferase (SULT1A1) in the outer root sheath cells of the follicle. This conversion step is essential: the parent compound (minoxidil) is relatively inactive. Minoxidil sulfate is what actually opens the potassium channels.
Critically: approximately 20–30% of men have insufficient SULT1A1 activity. These men do not convert topical minoxidil effectively — which is why they're non-responders to topical application. Oral minoxidil bypasses this step, converting systemically in the liver instead.
KATP Channel Opening — The Core Mechanism
Minoxidil sulfate opens ATP-sensitive potassium channels in smooth muscle cells surrounding the blood vessels near hair follicles. When these channels open, potassium ions flow out of the cell, causing hyperpolarization — the cell's electrical potential changes in a way that keeps calcium channels closed.
The smooth muscle relaxes, the blood vessel dilates. Blood flow to the follicle increases. The dermal papilla — which depends on blood supply for its function — receives more oxygen, nutrients, and growth factors.
VEGF Upregulation — Building New Capillaries
Minoxidil upregulates VEGF (vascular endothelial growth factor) in the dermal papilla cells. VEGF is a signaling protein that promotes the formation of new blood vessels (angiogenesis). This isn't just dilating existing vessels — it's building new capillary networks near follicles.
This may explain why minoxidil's effects are progressive — the vascular infrastructure around follicles physically improves over the course of months. It also may explain part of the permanence question: new capillary networks don't vanish immediately when minoxidil is stopped.
Prostaglandin E2 Upregulation — Direct Growth Signal
Minoxidil upregulates Prostaglandin E2 (PGE2), a lipid signaling molecule that is a known promoter of hair growth. PGE2 acts directly on follicle cells to promote anagen (growth phase) initiation and maintenance. This is the opposite of PGD2 (Prostaglandin D2), which suppresses hair growth and is elevated in bald scalp areas.
Anagen Phase Prolongation — The Net Result
The combined effect of improved blood supply, VEGF-mediated capillary growth, and PGE2 signaling is that follicles are pushed from telogen (rest) into anagen (growth) earlier than they otherwise would be — and stay in anagen longer. The anagen phase is when hair grows. Longer anagen = more growth per cycle = thicker, longer hair.
This is also what drives the month-3 shedding: minoxidil pushes resting hairs into anagen prematurely, which first requires the old telogen hair to be shed. The shed is the mechanism, not the side effect.
Dermal Papilla Enlargement
With sustained stimulation, the dermal papilla — the key signaling structure at the base of the follicle — actually enlarges. Dermal papilla size directly determines hair shaft diameter. A larger papilla produces a thicker hair. This is the biological explanation for vellus-to-terminal conversion: it's not a change in hair type per se, it's the follicle physically growing a larger command center capable of supporting a thicker, longer hair.
What Minoxidil Doesn't Do
Understanding the mechanism also clarifies common misconceptions about what minoxidil doesn't do — which matters for setting expectations and understanding why it works differently from other treatments.
Does not block DHT
No interaction with the androgen pathway. Finasteride blocks DHT. Minoxidil doesn't. Completely separate mechanism.
Does not affect hormones
Testosterone and DHT levels are unchanged by minoxidil use. It works through vasodilation, not endocrine signaling.
Does not create new follicles
Minoxidil activates dormant follicles and enlarges existing ones. It cannot generate follicles where none exist.
Does not work without follicles
Areas of skin with no follicles present will not respond. Minoxidil stimulates follicle activity — it doesn't create it.
Oral minoxidil is absorbed through the gut, converted to minoxidil sulfate in the liver (not the skin), and delivered systemically through the bloodstream. Men who lack sufficient skin-level SULT1A1 enzyme activity (topical non-responders) can still convert oral minoxidil effectively. This is why oral is the escalation path for men who see no response from topical after 6 consistent months.
Why the Mechanism Works Differently on Beard vs Scalp
Minoxidil's vasodilation mechanism is the same on beard and scalp. The difference in outcomes comes from what happens after the follicle is stimulated — specifically the androgen environment those follicles exist in.
On the scalp (in men with androgenetic alopecia): DHT is actively miniaturizing follicles. Minoxidil's vasodilation counteracts this somewhat but doesn't address the underlying DHT effect. When you stop minoxidil on the scalp, DHT resumes its miniaturizing influence. Scalp gains are not permanent without ongoing treatment (or DHT blocking with finasteride).
On the beard: DHT is a growth promoter (see the androgen paradox). Minoxidil stimulates follicles into anagen and drives vellus-to-terminal conversion. Once terminal, beard hairs are androgen-sustained — DHT maintains them. When you stop minoxidil on the beard, DHT doesn't reverse the growth. Terminal hairs remain. This is the biological basis for permanent beard gains from minoxidil.
Now That You Know How It Works — Start Putting It to Work
Happy Head's prescription formula is designed with enhanced penetration agents to maximize the amount of minoxidil sulfate that reaches your follicles. Less wasted, more effect.
FAQ
The practical test: 6 months of consistent, correct topical minoxidil use with zero response — not even vellus hairs in the target area. This suggests insufficient SULT1A1 conversion. Formal sulfotransferase enzyme testing exists but isn't widely available or routinely ordered. The clinical approach is simply to switch to oral minoxidil (via prescription) which converts in the liver and bypasses the skin enzyme entirely.
Potentially, yes. Penetration enhancers like propylene glycol (in liquid formulas) or the proprietary enhancers in prescription compounded formulas can increase the amount of minoxidil that reaches the follicle level. This is one argument for prescription compounded formulas over OTC foam — better delivery means more minoxidil sulfate at the site of action. Whether this translates to meaningfully better results varies by individual.
Exercise and massage do increase blood flow to skin, and some evidence suggests scalp massage has modest hair growth benefits. But minoxidil's effect goes beyond simple vasodilation — the VEGF upregulation (which builds new capillaries), PGE2 signaling (direct growth promoter), and the anagen-specific effects are all specific to the KATP channel mechanism. General blood flow increases from exercise don't replicate these targeted effects.